Skip to main content
TipRanks
Go Ultimate75% OFF

CryoPort (CYRX) AI Stock Analysis

651 Followers
CYRX

CryoPort

(NASDAQ:CYRX)

Select Model
Rating:51Neutral
Price Target:$16.00▼(-18.95% Downside)
Action:reiterated
Date:11/06/26

The score is held back primarily by weak financial quality despite strong top-line growth—losses persist and free cash flow remains materially negative. Technical signals are also bearish (negative MACD, RSI ~40, and price below key short-term moving averages). Offsetting these factors, the latest earnings call was constructive with raised revenue guidance and a second straight quarter of positive adjusted EBITDA, but execution risks (application delays, conservative Q4 outlook, and limited China growth) remain.

Positive Factors
Cell and Gene Therapy Market GrowthCryoport operates in a cell and gene therapy market that management expects to expand rapidly over several years. This structural growth can increase demand for temperature-controlled logistics, monitoring, and specialized fulfillment while creating opportunities to scale alongside therapy commercialization.
Negative Factors
Persistent Net LossesStrong revenue growth has not yet translated into sustained bottom-line profitability. Continued EBIT and net losses reduce internal capital generation, weaken returns to shareholders, and leave the business dependent on further operating improvement to establish a durable earnings base.

CryoPort Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.

-$20.00M$0.00$20.00M$40.00M$60.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Americas is the clear growth engine—its steady recovery and the Q1 beat tie directly to commercial cell‑and‑gene and clinical‑trial momentum—while APAC and EMEA have materially weakened, with APAC collapsing after a lumpy spike and EMEA trending down (including a discrete negative quarter), creating geographic concentration risk. Management’s cautious, modest guide lift and planned Paris/Santa Ana capacity ramps imply they expect Americas and commercial conversions to carry 2026, but failure to stabilize APAC/EMEA could meaningfully cap upside until multi‑quarter facility and IntegraCell ramps complete.

Data provided by:The Fly

CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%CYRX+124.83%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$999.81M
Dividend Yield
―
Average Volume (3M)
808.55K
Price to Earnings (P/E)
-22.1
Beta (1Y)
1.18
Revenue Growth
1.15%
EPS Growth
21.02%
Country
US
Employees
688
Sector
Industrials
Sector Strength
63
Industry
Integrated Freight & Logistics

CryoPort Business Overview & Revenue Model

Company Description

Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to t...

How the Company Makes Money

CryoPort primarily makes money by selling logistics services and related solutions that enable the compliant, temperature-controlled movement of sensitive life-science materials. Key revenue streams include: (1) Cryogenic and cold-chain logistics ser...

CryoPort Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:22.99%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive. Cryoport reported 14% revenue growth, 18% growth in Life Sciences Services, 20% growth in commercial cell and gene therapy activity, a record clinical trial pipeline, positive adjusted EBITDA for the second consecutive quarter, and increased full-year revenue guidance. Management also highlighted expanding bioservice capabilities, continued MVE demand, and a favorable cell and gene therapy market outlook. The main challenges were delayed applications, limited China growth, cyclical animal health demand, selective margin impact from facility expansions, and conservative fourth-quarter guidance.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue was $50.2 million, representing 14% year-over-year growth. Management said the growth was broad-based across both Life Sciences Services and Life Sciences Products.

Negative Updates

Some Expected Applications Shifted to 2027
Four applications that management previously expected to occur in 2026 were pushed into 2027.

Company Guidance

Cryoport raised full-year 2026 revenue guidance to $197 million to $199 million, representing 12% growth year-over-year, with “upside potential for that as well”; the implied Q4 revenue range was $50 million to $52 million, with guidance described as “prudent,” “conservative,” and reflecting a “minimum,” and new approvals are “really not baked into the guidance.” For the remainder of 2026, the company expects “5 possible BLA/MAA application filings,” “2 potential new therapy approvals,” and “1 additional supplemental approval for geographic expansion,” with 1 approval scheduled in November and 1 in December, while 4 applications were pushed into 2027. MVE is expected to deliver “solid mid-single-digit growth on a continued basis,” China represents “about 3% to 4%” of total revenue with “no significant growth,” and biostorage and bioservices are expected to continue as a “double digit grower.” Long-term goals are 55% gross margin and 30% adjusted EBITDA, with “further EBITDA margin expansion in 2027 and beyond,” while cell and gene therapies are expected to grow at a “6 year 30-34% CAGR” from $10.2 billion in 2025 to roughly $60 billion in 2030.

CryoPort Financial Statement Overview

Summary

Revenue growth is very strong (TTM +321.1%) and gross margin is steady (~47%), but profitability remains negative (EBIT and net income losses; ~-22% net margin). The balance sheet looks reasonably levered (debt-to-equity ~0.48) yet returns are negative due to losses. Cash flow is a key risk: operating cash flow is positive (~$11.0M) but free cash flow remains meaningfully negative (~-$18.3M) and cash conversion has been inconsistent.

Income Statement

44Neutral

Balance Sheet

63Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2020
Income Statement
Total Revenue192.44M176.18M233.25M237.28M222.61M222.61M
Gross Profit90.28M83.05M99.33M103.87M96.58M96.58M
EBITDA-7.21M-2.10M-63.09M-1.47M-246.39M-248.91M
Net Income-40.18M78.30M-99.59M-37.33M-275.53M-275.53M
Balance Sheet
Total Assets750.95M764.99M703.49M957.74M1.04B1.11B
Cash, Cash Equivalents and Short-Term Investments393.08M411.21M261.75M456.75M523.32M628.80M
Total Debt231.51M230.72M250.70M416.00M435.91M427.06M
Total Liabilities267.43M262.35M301.59M468.72M482.91M471.14M
Stockholders Equity483.51M502.64M401.90M489.02M555.84M641.83M
Cash Flow
Free Cash Flow-18.28M-28.09M-33.58M-45.66M-26.05M-16.88M
Operating Cash Flow11.00M-8.58M-16.32M-757.00K-1.85M8.13M
Investing Cash Flow17.13M250.32M176.81M36.05M-59.68M-469.25M
Financing Cash Flow-1.20M-21.07M-161.53M-23.80M-39.17M564.34M

CryoPort Technical Analysis

Technical Analysis SentimentPositive
Last Price19.74

Price Trends

50DMA17.60Positive
100DMA16.65Positive
200DMA13.81Positive

Market Momentum

MACD0.75Negative
RSI59.76Neutral
STOCH68.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 19.74 is above the 20-day moving average (MA) of 18.53, above the 50-day MA of 17.60, and above the 200-day MA of 13.81, indicating a bullish trend. The MACD of 0.75 indicates Negative momentum. The RSI at 59.76 is Neutral, neither overbought nor oversold. The STOCH value of 68.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Risk Analysis

CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Further impairment of our goodwill or intangible assets could have a material non-cash adverse impact on our results of operations.Q4, 2023

CryoPort Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

CYRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EXPDEXPD78Outperform$24.63B24.1545.78%0.83%18.64%28.14%
FDXFDX70Outperform$74.93B19.5212.56%1.49%3.09%14.94%
UPSUPS66Neutral$93.93B21.2328.51%5.95%2.29%-19.62%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
CHRWCHRW62Neutral$15.99B24.3639.59%1.83%10.38%12.97%
GXOGXO54Neutral$6.21B46.564.56%―7.08%54.11%
CYRXCYRX51Neutral$1.00B-22.11-8.15%―1.15%21.02%

* Industrials Sector Average

Performance Comparison

0%50%100%CYRXCHRWEXPDFDXUPSGXODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CYRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CYRXCryoPort Inc19.7411.37135.84%
CHRWCh Robinson Worldwide137.95-8.39-5.73%
EXPDExpeditors International Of Washington190.7753.9039.38%
FDXFedEx Corporation319.94111.6153.58%
UPSUnited Parcel Service110.3124.8329.04%
GXOGxo Logistics Inc54.958.7418.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026